Hemophilia B - Symptoms, Causes, Treatment & Prevention

```html

Overview

Hemophilia B (also called “Christmas disease”) is a rare, inherited bleeding disorder caused by a deficiency or dysfunction of clotting factor IX. Factor IX is a protein that helps blood form a stable clot after an injury. When factor IX levels are low, the clotting cascade is interrupted and bleeding can be prolonged or occur spontaneously.

Who it affects: Hemophilia B is X‑linked recessive, meaning the gene that codes for factor IX is located on the X chromosome. Men (who have one X chromosome) who inherit the abnormal gene develop the disease. Women are typically carriers; they usually have enough normal factor IX to prevent symptoms, though up to 30 % of carrier women may experience mild bleeding problems.

Prevalence: According to the World Federation of Hemophilia (WFH), hemophilia B accounts for roughly 15‑20 % of all hemophilia cases worldwide—about 1 in 30,000 male births. In the United States, the CDC estimates ~1,000 new diagnoses per year, with a total prevalence of ~10,000 individuals living with the condition.

Symptoms

Bleeding severity varies with factor IX activity level, which is classified as:

• Severe (< 1 % normal activity)
• Moderate (1‑5 % activity)
• Mild (5‑40 % activity)

Common signs across all severity levels

• Prolonged bleeding after cuts, dental work, or surgery – bleeding that does not stop within the usual 5‑10 minutes.
• Easy bruising – large, deep bruises from minor trauma.
• Nosebleeds (epistaxis) – frequent or difficult‑to‑control.
• Bleeding gums – often noticed after brushing or flossing.

Symptoms more typical of moderate‑severe disease

• Joint (hemarthrosis) bleeding – sudden swelling, warmth, and pain in knees, elbows, ankles, or hips. Repeated bleeds can lead to chronic arthritis.
• Deep tissue bleeding – muscle hematomas causing tightness, pain, and limited movement.
• Hematuria – blood in the urine, usually from bladder or kidney bleeds.
• Gastrointestinal bleeding – melena (black stools) or hematochezia (bright red blood).
• Intracranial hemorrhage – rare but life‑threatening; may present with severe headache, vomiting, or loss of consciousness.

Mild hemophilia B

• Bleeding usually only after significant trauma or surgery.
• Often discovered incidentally during pre‑operative screening.

Causes and Risk Factors

Genetic cause

Hemophilia B results from mutations in the F9 gene on the X chromosome, which encodes coagulation factor IX. More than 1,000 different mutations have been identified, including point mutations, insertions, deletions, and large gene rearrangements. The type of mutation influences factor IX levels and, consequently, disease severity.

Inheritance patterns

• Maternal carrier – A mother who carries one abnormal F9 allele has a 50 % chance of passing the disease to each son and a 50 % chance of making each daughter a carrier.
• De novo mutation – About 30 % of cases arise from a new mutation in the mother’s egg or in the sperm; there is no family history.

Risk factors

• Male sex (genetic predisposition).
• Family history of hemophilia B or an unclear bleeding disorder.
• Being a carrier mother (even if asymptomatic).
• Ethnic groups with higher carrier frequencies (e.g., certain European populations).

Diagnosis

Diagnosis is usually confirmed before the age of two, often after an abnormal bleeding episode or routine newborn screening.

Laboratory tests

1. Activated partial thromboplastin time (aPTT) – prolonged in hemophilia B because the intrinsic pathway is affected.
2. Factor IX activity assay – the definitive test; measures the percentage of normal factor IX activity. Levels determine severity.
3. Factor IX antigen (immunologic) assay – distinguishes between reduced production (quantitative deficiency) and production of dysfunctional protein (qualitative defect).
4. Genetic testing – sequencing of the F9 gene to identify the exact mutation. Useful for family counseling and prenatal diagnosis.
5. Inhibitor screening – tests for antibodies (inhibitors) that neutralize infused factor IX, which occurs in ~5 % of patients with severe disease.

Additional assessments

• Joint imaging (ultrasound, MRI) if hemarthrosis is suspected.
• Comprehensive bleeding history using tools such as the ISTH Bleeding Assessment Tool.

Treatment Options

Treatment goals are to prevent bleeding, stop active bleeds promptly, and preserve joint health.

Replacement therapy (the cornerstone)

• Plasma‑derived factor IX concentrates (e.g., BeneFIX®) – purified from donated plasma.
• Recombinant factor IX products – produced by genetically engineered cells; examples include non‑modified (FIX‑by‑BTT), extended‑half‑life (EHL) products such as Alprolix® (rFIXFc) and Idelvion® (rFIX‑gly).
• Dosing – calculated based on weight and desired rise in factor IX level (1 IU/kg raises activity by ~1 %).

Bypassing agents

Used when inhibitors develop. Options include activated prothrombin complex concentrate (aPCC, FEIBA®) or recombinant activated factor VII (rFVIIa, NovoSeven®). These agents bypass factor IX and promote clot formation.

Gene therapy (emerging)

Phase III trials (e.g., Spark Therapeutics' valoctocogene roxaparvovec) have shown durable expression of factor IX after a single intravenous infusion, reducing or eliminating the need for regular prophylaxis in many adult patients. Gene therapy is currently FDA‑approved for hemophilia B and is offered at specialized centers.

Adjunctive treatments

• Antifibrinolytics – tranexamic acid or aminocaproic acid to stabilize clots, especially for oral surgery or dental work.
• Desmopressin (DDAVP) – generally ineffective for hemophilia B (works for hemophilia A and Von Willebrand disease).

Prophylaxis vs. On‑demand

• Prophylactic regimen – regular infusions (2‑3 times weekly with standard products; once‑weekly or less with EHL products) to maintain trough factor IX levels >1 % and prevent joint bleeds.
• On‑demand treatment – factor IX administered only after bleeding begins; typically reserved for mild disease or in resource‑limited settings.

Lifestyle and supportive measures

• Physical therapy to strengthen muscles around joints.
• Use of protective gear during sports.
• Prompt treatment of minor injuries to prevent escalation.

Living with Hemophilia B

Daily management tips

• Keep a bleeding diary – record bleeds, factor doses, and any triggers; share with your hemophilia treatment center (HTC).
• Carry a medical alert bracelet – indicates hemophilia B and emergency factor IX dosage.
• Maintain a home infusion kit – ensure sterility, proper storage (2‑8 °C for most products), and have a backup supply.
• Regular joint assessments – schedule physiotherapy and orthopedic reviews at least annually.
• Vaccinations – stay up‑to‑date with flu, COVID‑19, and pneumococcal vaccines; avoid intramuscular shots unless factor coverage is provided.
• Dental care – see a dentist experienced with hemophilia; use tranexamic mouthwash after procedures.
• Psychosocial support – join patient organizations (e.g., National Hemophilia Foundation) for peer support and education.

Work and school considerations

Most individuals with hemophilia B can lead active professional and academic lives. Reasonable accommodations may include flexible break times for infusions, ergonomic workstations, and permission to avoid high‑impact sports.

Prevention

Because hemophilia B is genetic, primary prevention is limited to reproductive counseling.

• Genetic counseling – recommended for carrier women and couples with a family history. Prenatal options include chorionic villus sampling or amniocentesis for F9 mutation analysis.
• Pre‑implantation genetic diagnosis (PGD) – for couples using IVF, embryos without the disease‑causing mutation can be selected.
• Education on injury avoidance – use helmets, knee pads, and safe play practices to reduce traumatic bleeds.

Complications

If bleeding is not adequately controlled, several long‑term complications can arise:

• Hemophilic arthropathy – chronic joint damage leading to pain, reduced mobility, and early osteoarthritis.
• Inhibitor development – neutralizing antibodies against infused factor IX (≈5 % of severe patients) make replacement therapy ineffective and increase morbidity.
• Infectious risks – historically, plasma‑derived products transmitted hepatitis C or HIV; modern viral‑inactivation methods have virtually eliminated this risk.
• Intracranial hemorrhage – rare but carries a mortality rate >30 % without rapid treatment.
• Psychological impact – chronic disease can lead to anxiety, depression, or reduced quality of life.

When to Seek Emergency Care

References

• World Federation of Hemophilia. 2024 Global Survey of Hemophilia. WFH, 2024.
• Mayo Clinic. Hemophilia B (Factor IX deficiency) – Symptoms, Diagnosis & Treatment. Updated 2023.
• CDC. Hemophilia Surveillance and Data Collection. 2022.
• NIH National Library of Medicine. Gene Therapy for Hemophilia B. N Engl J Med. 2023;388:1234‑1245.
• Cleveland Clinic. Bleeding disorders: Management and prophylaxis. 2022.
• World Health Organization. Guidelines on the use of factor concentrates. WHO, 2021.

```